4.6 Article

Efficacy of Eight Months of Nightly Zolpidem: A Prospective Placebo-Controlled Study

期刊

SLEEP
卷 35, 期 11, 页码 1551-1557

出版社

OXFORD UNIV PRESS INC
DOI: 10.5665/sleep.2208

关键词

Primary insomnia; zolpidem; hypnotics; randomized controlled trial

资金

  1. NIDA [R01DA17355]
  2. Aventis
  3. Cephalon
  4. Glaxo Smith Kline
  5. Merck
  6. Neurocrine
  7. Pfizer
  8. Sanofi
  9. Schering-Plough
  10. Sepracor
  11. Somaxon
  12. Somnus
  13. Syrex
  14. Takeda
  15. TransOral
  16. Ventus
  17. Wyeth
  18. Xenoport

向作者/读者索取更多资源

Study Objectives: To evaluate the long-term (8 months) efficacy of zolpidem in adults with chronic primary insomnia using polysomnography. Design: Randomized, double-blind, placebo-controlled clinical trial. Setting: Sleep disorders and research center. Participants: Healthy participants (n = 91), ages 23-70, meeting DSM-IV-TR criteria for primary insomnia. Interventions: Nightly zolpidem, 10 mg (5 mg for patients >60 yrs) or placebo 30 minutes before bedtime for 8 months. Measurements and Results: Polysomnographic sleep parameters and morning subject assessments of sleep on 2 nights in months 1 and 8. Relative to placebo, zolpidem significantly increased overall total sleep time and sleep efficiency, reduced sleep latency and wake after sleep onset when assessed at months 1 and 8. Overall, subjective evaluations of efficacy were not shown among treatment groups. Conclusions: In adults with primary insomnia, nightly zolpidem administration remained efficacious across 8 months of nightly use.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据